JPRN-jRCT2080223505
Completed
Phase 3
A Multicenter, Randomized, Double-Blind Trial in Subjects with Non-Squamous Non-Small Cell Lung Cancer(ONO-4538-52/TASUKI-52)
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- ONO PHARMACEUTICAL CO.,LTD.
- Enrollment
- 530
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Subjects with histologically\- or cytologically\-confirmed non\-squamous non\-small cell lung cancer
- •2\. Subjects who received a diagnosis of stage IIIB/IV or recurrent non\-squamous non\-small cell lung cancer
- •3\. Subjects with at least one measurable lesion by radiographic tumor assessments per RECIST 1\.1 criteria
Exclusion Criteria
- •1\. Complication or history of severe hypersensitivity reactions to antibody products or platinum\-containing compounds
- •2\. Subjects with multiple cancer
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A Multicenter, Randomized, Double-Blind Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone For The Treatment of Antiretroviral-Experienced Non CCR5-Tropic HIV-1 Infected SubjectEUCTR2004-001779-20-ITPfizer LTD, Pfizer Global RD-Sandwich Laboratories-I.P.C. 582192
Active, not recruiting
Phase 1
A Multi-center, Randomised, Double-blind Trial of Nintedanib in Lung Transplant (LTx) recipients with bronchiolitis obliterans syndrome (BOS) grade 1-2Bronchiolitis Obliterating Syndrome (SBO) grade 1 or 2 in patients with pulmonary transplantation.MedDRA version: 20.0 Level: PT Classification code 10029888 Term: Obliterative bronchiolitis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2018-001747-31-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)80
Recruiting
Not Applicable
Double-blind Randomized Multi-center Trial Regarding the Effects of Solution for Gemcitabine on Frequency and Degree of Vascular Pain in Patients with CancerJPRN-UMIN000001827Tohoku University Translational Research Center90
Unknown
Phase 3
A Double-Blind, Randomized, Multicentre Trial Comparing the Efficacy and Tolerability of 250mg of Faslodex (Long Acting ICI 182,780) With 20mg of Nolvadex (Tamoxifen) in Postmenopausal Women With Advanced Breast CancerBreast Cancer MetastasisJPRN-jRCT2080220407AstraZeneca
Active, not recruiting
Not Applicable
A Multicenter Randomized Double-Blind Trial Comparing Rosiglitazone to Placebo for the Prevention of Atherosclerosis Progression after Coronary Bypass Surgery in Diabetic Patients - THE VICTORY TRIAEUCTR2005-000013-36-ESDr. Olivier F. Bertrand , Laval Hospital280